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ABSTRACT
Through the photosynthetic activity, microalgae process more than 25% of annual inorganic carbon dissolved in
oceans  into  carbohydrates  that  ultimately, serve  to  feed  the  other  levels  of  the  trophic  networks.  Besides,
microalgae synthesize bioactive molecules such as pigments and lipids that exhibit health properties. In addition,
abiotic  stresses,  such as high irradiance,  nutrient  starvation,  UV  irradiation,  trigger  metabolic  reorientations
ending with the production of other bioactive compounds such as ω-3 fatty acids or carotenoids. Traditionally,
these compounds are acquired through the dietary alimentation. The increasing, and often unsatisfied, demand
for compounds from natural sources, combined with the decrease of the halieutic resources, forces the search for
alternative resources for these bioactive components. Microalgae possess this strong potential. For instance, the
diatom Odontella aurita is already commercialized as dietary complement and compete with fish oil for human
nutrition. In this contribution, the microalga world is briefly presented. Then, the different types of biologically
active molecules identified in microalgae are presented together with their potential use. Due to space limitation,
only  the  biological  activities  of  lipids and  pigments  are  described in  details.  The  contribution ends  with  a
description  of  the  possibilities  to  play  with  the  environmental  constrains  to  increase  the  productivity  of
biologically active molecules by microalgae and by a description of the progresses made in the field of alga
culturing. 
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INTRODUCTION
More than 70% of Earth is covered with water, in which the most dominant group of living organisms is that of 
algae. Algae belong to the plant phylum. They are mostly living in water while they have colonized every type of
ecological niche. The preferences of individual algal species, which determine their geographical distribution, 
are based on their environmental tolerance and their responses to abiotic interaction. On the other hand, natural 
populations are morphologically, physiologically and biochemically diverse because of genetic variability and 
abiotic conditions [1]. 
Algae have a tremendous impact on the sustainability of the marine ecosystem as being the primary producers 
[2] and, therefore, a food source for other marine organisms. Their potential is not restricted to this point as 
through feeding of other organisms placed at higher levels in the food chain can take benefit from particular me-
tabolites such as photoprotective compounds [3]. On the basis of their constituting number of cells, algae can be 
grouped as unicellular or pluricellular organisms, these terms being often taken as synonym for microalgae or 
phytoplankton and macroalgae, respectively. Algae represent a few percentage among the total number of 
species described so far (Fig. S1) even though the number of species is probably largely underestimated [4]. This
is especially true for microalgae. The use of algae as fertilizers and food is established since the antiquity. Con-
sidering the increasing need of food, bioenergy, pharmaceutical and cosmetic compounds, a particular attention 
has been paid for the last decade to sustainable resources that do not compete with usual food resources. Mi-
croalgae are pretty good candidates for such a purpose and their long evolutionary and adaptive diversification 
has led to a large and diverse array of biochemical constituents. Amazingly, the development of industrial pro-
cesses using algae remains weak (15 106 T produced/year) when compared to the field production (4 109 T pro-
duced/year) [4], probably because of their typical weak growth rate compared [5]. Therefore, the improvement of
culturing performances constitutes the best way to make alga cost-competitive. This can be achieved through a 
deep knowledge of algal biochemistry and physiology and obviously through optimization of bioreactors. Never-
theless, numerous new molecules are isolated, described at the atomic level and tested for their biological activi-
ties, as testified by the increasing number of publications on this topic found in databases (total number of papers
published between 1964 and 2011 = 705) (Fig. S2). This amount remains however very small when compared 
with the number of papers published about molecules originating from higher plants (> 13000) [1, 6-10]. Until 
recently, it was thought that the metabolism of algae is close to that of higher plants. However, the interpretation 
of sequenced genomes established the originality of the algal metabolism and will bring information about pri-
mary and secondary metabolisms, and the presence of key molecules (e.g., [11]).
5
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
Current Pharmaceutical Biotechnology                                                                                   Mimouni et al.
In this contribution, the microalga world is first briefly overviewed. Then the different types of biologically 
active molecules identified in microalgae are presented together with their potential use. Due to space limitation, 
only the biological activities of lipids and pigments are discussed in details. The contribution ends with a 
description of the possibilities to play with the environmental constrains to increase the productivity of 
biologically active molecules by microalgae and of the progresses made in the field of alga culturing. The data 
presented in this manuscript are limited to the eukaryotic microalgae producing molecules with a biological 
activity. Molecules isolated from macroalga or dealing with other usages will not be covered here and the 
interested reader is invited to read the excellent papers published on these topics (e.g., [3,6-7,12-14]).
THE MICROALGA WORLD: A BRIEF OVERVIEW
Algae is a generic term used to designate eukaryotic organisms sharing photoautotrophy (most of the species) 
and the absence of land plant characteristics such as trachea. From the evolution point of view, alga is a 
polyphyletic group of taxons, all deriving from the internalization of a cyanobacterium-type organism into a 
eukaryotic heterotrophic cell. This explains why actual chloroplasts are surrounded by two envelopes [15-17]. 
On the basis of the chloroplast pigments, three lineages are currently considered as distinct evolutionary clusters 
of taxa [15-17]: 
- The blue lineage of primary endosymbionts in which chlorophyll a (Chl a) is the only Chl-type of molecule 
and the chloroplast still contains a peptidoglycan cell wall typical of cyanobacteria. These organisms being 
not eukaryotes, this lineage is not presented here. 
- The red lineage of primary endosymbionts in which Chl a is also the only Chl-type of molecule. Belong to 
this lineage more than 6,000 species, mostly unicellular and marine, including many notable seaweeds, of red
algae or Rhodophyta. Subcellular and phylogenetic analyses revealed that red algae are one of the oldest 
groups of algae [18-19]. The oldest fossil eukaryote so far identified is a red alga and was found in rocks 
dating to 1,200 million years ago [20]. 
- The green lineage of primary endosymbionts in which Chl a is associated to Chl b. Belongs to this lineage the
green algae or Chlorophyta (more than 6,000 species), from which the higher plants emerged. Chlorophyta 
forms a paraphyletic group of unicellular, colonial, coccoid, caenobial and filamentous forms as well as 
seaweeds. 
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To explain the presence of additional membranes around the chloroplasts, a secondary endosymbiotic act is 
usually invoked. The members of the red lineage of secondary endosymbionts constitute a very diverse group of 
organisms, the most important from the pharmaceutical point of view being the diatoms (Heterokonta) and the 
dinoflagellates (Alveolata). 
Diatoms
With 250 orders and more than 105 species, the diatom taxon is one of the most diverse group of microalgae [21].
Diatoms are thought to contribute as much as 25% of the Earth primary productivity [22]. Diatoms have the 
unique property to have a siliceous cell wall and are characterized by a typical pigment composition: chlorophyll
c as accessory Chl molecule and fucoxanthin as the main carotenoid [23-24]. Diatoms are used in aquaculture to 
feed mollusks whereas several intracellular metabolites such as lipids (eicosapentaenoic acid (EPA), 
triacylglycerols) and amino acids are extracted and used by pharmaceutical and cosmetic industries [25-26]. 
Beside these compounds, diatoms may excrete toxins, pigments and antibiotics. 
Dinoflagellates
It is a large group of photosynthetic organisms thought a large fraction are in fact mixotrophic cells i.e. 
combining photosynthesis with ingestion of prey [27]. Some species live in symbiosis with marine animals 
(called zooxanthellae). As diatoms, dinoflagellates use Chl c as an accessory pigment. Dinoflagellata are mostly 
known for red tides and the neurotoxins released during such a phenomenon. 
MICROALGAE: NATURAL FACTORIES FOR BIOLOGICAL MOLECULES IMPORTANT FOR 
HEALTH
Toxins
Toxic compounds are mostly produced by dinoflagellates and diatoms, although not every specie produces this 
type of compound. For instance, the dinoflagellates Alexandrium sp., Karenia brevis (previously Gymnodinium 
breve) produces paralytic shellfish toxins saxitoxin (1) [28] and brevetoxin-B (2). This last toxin is responsible 
for neurologic disorders [29]. A single taxon can synthesize several toxins (Table S1). The blooms may cause hu-
man irritation of eyes and throat in the coastal area. Occasionally, the consumption of contaminated shellfishs re-
sults in human poisoning, the prominent symptoms being gastrointestinal disorders. Beside these toxins, the di-
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noflagellate Amphidinium klebii produces different groups of macrolides such as amphidinol-7 (3) [30] exhibit-
ing extremely potent cytotoxicity against L1210 cells i.e. mouse lymphocytic leukemia cells and antifungus ac-
tivity [29]. Goniodoma pseudogonyaulax excretes antimicrobial and antifungal substances such as goniodomin-
A (4) [31-32]. In addition, goniodomoin A has been shown to inhibit angiogenesis [33]. Prorocentrum lima and 
Dinophysis sp. synthesize okadaic acid, a protein dephosphorylation inhibitor and Gambierdiscus toxicus pro-
duces ciguatoxin and maitotoxin that cause diarrhetic disturbances (Table S1). Gambierdiscus toxicus also pro-
duces fungus growth inhibitors, the gambieric acids [29] (Table S1).
Several diatom species have been reported to synthesize domoic acid (5) (Table S1) [34], a tricarboxylic acid an-
tagonist of the neuroexcitatory glutamate insecticidal properties [25] that can be fatal after accumulating in shell-
fish, some of which being able to retain high level of this compound [35]. Domoic acid was found to be very ef-
fective in expelling ascaris and pinworms [29].
Pigments: As mentioned earlier, most of the algae are photoautotrophs. Consequently, their chloroplasts are rich 
in pigmented molecules such as tetrapyrroles and carotenoids. The molecules are able to absorb light thanks to 
their characteristic conjugated double bonds. Each photosynthetizing microalga contains at least the close 
tetrapyrrole Chl a (6). Except in red algae, in which Chl a is accompanied by the open tetrapyrroles 
phycoerythrin, phycocyanin and allophycocyanin, green and brown algae contain another type of Chl molecule 
(Table 1). The set of light harvesting molecules is complemented with several carotenoids (Car) (Table 1). As it 
will be explained below in details, these molecules have a great health and therapeutic potential. 
The diatom Haslea ostrearia synthesizes and excretes a hydrosoluble blue pigment, the so-called 
marrenine, responsible for the greening of oyster gills [7]. This pigment exhibits an antiproliferative effect on 
lung cancer model [36] and has potential antiviral and anticoagulant properties [37]. 
Amino acids: Beside the universal functions of amino acids in proteins, they are important for skin hydration, 
elasticity, photoprotection (see below) and are included in cosmetics [7]. Amino acids from diatoms exhibit 
dermatological properties [38]. 
Photoprotectants: The best known photoprotectants synthesized by microalgae are mycosporine-like amino 
acids (MAAs) (Fig. S3). MAAs act as sunscreens to reduce UV-induced damage and also as ROS scavengers 
[39]. Mycosporine-like amino acids have been found in more than 380 marine species, including microalgae 
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[40]. A database referencing the studies in microalgae, cyanobacteria and macroalgae is available at the Univer-
sity of Erlangen, Germany (http://www.biologie.univ-erlangen.de/botanik1/html/eng/mar-
database.htm). A recent study reported the screening of 33 different species belonging to 13 classes of microal-
gae for MAAs [40]. The highest concentrations were found in dinoflagellates whereas diatoms contained only 
low amounts. MAAs have the potential to replace or supplement today’s available sunscreens and particularly 
those based on petrochemical products. More recently, other photoprotective molecules such as pyropheophytin 
a (Eicenia bicyclis: [41]), fucoxanthin (Fuco) (Hijikia fusiformis: [42]) have been isolated from brown macroal-
gae [3,29]. Because these molecules are also present in microalgae, they have been also considered here. Jeffrey 
et al. [43] have reported the occurrence of such compounds in 206 strains of 152 microalgae. In many microal-
gae, the cell is made more resistant to UV by the accumulation in the cell wall of sporopollenin [44], a Car-poly-
mer absorbing UV light. 
Lipids: In animal cells, essential fatty acids and specifically polyunsaturated fatty acids (PUFAs) are 
incorporated into lipid membranes in which they increase the fluidity and exchanges between extra and 
intracellular compartments. Numerous studies have demonstrated that dietary ω3 PUFAs have a protective effect
against atherosclerotic heart disease [45-48]. The two principal ω3 fatty acids in marine oils, eicosapentaenoic 
acid (EPA; 20:5ω3) (7) and docosahexaenoic acid (DHA; 22:6 ω3) (8), have a wide range of biological effects. 
Both EPA and DHA are known to influence lipoprotein metabolism, platelet and endothelial function, 
coagulation, and blood pressure. More specifically, EPA performs many vital functions in biological membranes,
and is a precursor of several lipid regulators involved in the cellular metabolism. In addition, the effect of ω3 
fatty acids may depend, to some extent at least, on the presence of underlying disorders such as dyslipidemia, 
hypertension, diabetes mellitus, and vascular diseases [48]. DHA is a major component of brain, eye retina and 
heart muscle, it has been considered as important for brain and eye development and also good cardiovascular 
health [49]. ω3 fatty acid supplementation in animals and humans results in substantial increases in the plasma 
and tissue levels of EPA and DHA, as well as variable incorporation of the phospholipid classes in various 
tissues. These differences may be important for the subsequent use and metabolism of EPA and DHA. Although 
both fatty acids are thought to be biologically active, most studies have focused on the relative importance and 
effects of EPA, primarily because of its predominance in marine oils and fish species. Because animal cells are 
unable to synthesize these molecules, they must be acquired through the diet. So far, the main source for PUFAs, 
free or methyl ester derivatives, fatty alcohols, fatty amines and glycerol is fishes. However, fish oil depends on 
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fish quality and fish resources, which are declining and fish tends to accumulate poisonous subtances via the 
food chain. Therefore, alternate sources have to be exploited. Microalgae present an excellent potential for this 
purpose because (i) their fatty acid profile is simpler than that of fish oil, (ii) the production condition can be 
controlled and last but not least, (iii) the algal species can be selected according to the PUFA required (see 
below). In contrast to EPA, molecules from fish oil products are unstable and exhibit a poor taste, EPA esters 
from microalgae are of better quality and more stable [50]. Importantly, selected PUFA can be favored through 
choosing culture conditions. Some species, such as Phaeodactylum tricornutum produce mainly EPA [51]. 
Among the lipids, arachidonic acid (Ara), an essential fatty acids, is produced by some algae such as Nitzschia 
conspicua [52]. Ara is also a precursor of prostaglandins and leukotrienes and, is also a component of mature 
human milk [53]. All these molecules can be used for different activities such as nutrition (human and animal), 
pharmaceutics, cosmetics, aquaculture and biodiesel production.
Polysaccharides
Best producers of polysaccharides of interest are brown and red seaweeds. Among the different types of 
polysaccharides synthesized by these algae and also synthesized by red microalgae such as Porphyridium sp., 
those that are highly sulfated present an antiviral activity [54-55]. 
Miscellaneous
In addition to their used in flavor and fragrance industries, monoterpenes have drawn increasing commercial 
attention because of their putative action as natural insecticides and antimicrobial agents [56]. Little is known 
about the production of these molecules in microalgae but their use as biotransformant has been reported [56]. 
Water extract of the marine diatom Haslea ostrearia exhibited anticoagulant activity [37].
Due to space limitation for this review and the availability of the data, only the lipids and pigments, as molecules
with biological activities, are detailed in the next section.
LIPIDS  AND  PIGMENTS,  TWO  TYPES  OF  BIOLOGICALLY  ACTIVE  COMPONENTS
SYNTHESIZED BY MICROALGAE
Lipids
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Fishes and marine microalgae are the primary producers of ω3 PUFA. While microalgae synthesize ω3 PUFA,
fishes  usually obtain EPA via bioaccumulation in the food chain. So far, two of the questions that have been
addressed  are: (i) is  it cheaper to produce  ω3 fatty acids from algae is than from fishes? and (ii) are  ω3 fatty
acids obtained  (EPA and DHA in particular)  from microalgae  as  effective  as  those  obtained  from fish  oil?
Regarding the first question, it was shown that ω3 fatty acid production from microalgae would indeed be less
expensive than the one from fishes. In addition, unlike fish oil, microalgal ω3 fatty acid extracts have no odour,
are  less susceptible  to be contaminated by heavy metals,  and do not contain cholesterol [57].  Finally,  when
microalgae are grown under controlled conditions, the composition of the fatty acids shows no seasonal variation
[58].  As fish oil fails to meet the increasing demand for purified PUFA, alternative sources are being sought,
especially from microalgae. Microalgae contain lipid levels between 20-50% (Table 2), but in stress conditions
such  as  N-deprivation  or  an  irradiance or  temperature  increase,  some  species  of microalgae  are  able,  to
accumulate up to 80% of their dry weight in fat [59-60], including large quantities of high-quality  ω3 PUFAs
(Table 2). Thus, algae are gaining increasing attention because of their important values for human health as well
as for aquaculture.
So far several algae are already used as dietary supplements. Chlorella sp., a freshwater unicellular green alga, is
known to be a good source of proteins, lipid soluble vitamins, pigments, choline, and essential minerals in a
bioavailable form. The administration of Chlorella affects some biochemical and physiological functions [71].
As  algal sources of DHA come the brown alga  Schizochytrium sp. (40% DHA, 17% docosapentaenoic acid
(DPA)),  the  green  alga  Ulkenia sp.  and  the  red  alga  Crypthecodinium  cohnii (40-50%  DHA)  [72].  The
production from the  latter species is especially well described [73] and marketed by Martek company. DHA
produced from microalgae is mainly used for child and adult dietary supplements [74]. Moreover, C. cohnii have
effects in aquaculture [75]. It has already been showed that algal oils rich in DHA are nutritionally equivalent to
fish oils in several tests [76-77], suggesting that algal oils could constitute a susbtitution to fish oils. In addition,
new algal  sources  for  the  ω3 very long chain  PUFAs (VLCPUFA)  are  being examined.  These  include  the
production of EPA from other strains such as marine diatoms. P. tricornutum, a marine diatom, has been widely
used as a food organism in aquaculture and considered as a potential source for EPA production [77]. The sole
marine microalga known to be rich in EPA used as a dietary supplement is the marine diatom O. aurita. It has
been shown that extracts of this microalga have an anti-proliferative effect on cultures of bronchopulmonary and
epithelial cells [78]. Different experimental models are used to conduct studies in relation with use of ω3 fatty
acids from microalga sources. Using freeze-dried microalgae, animals and specifically murine models are often
11
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
Current Pharmaceutical Biotechnology                                                                                   Mimouni et al.
used as previously described by several authors. Normal or modified (chemically and genetically) strains of mice
and rats have been already used to study the effects of Chlorella sp. on myelosupression induced by lead [79], on
glycogenesis improvement in diabetic mices [71] and on dyslipidemia prevention in rats fed with high fat diet
treatments [80]. The comparison of rats fed with freeze-dried O. aurita or with fish oil shows that the plasma
triacylglycerol concentration in rats fed microalgae was lower than in the control group and also than in the fish
oil  group  (Fig.  1).  The  plasma  concentrations  of  HDL-  and  LDL-cholesterol  were  significantly  higher  by
comparison with the control rats. For the rats fed with fish oil, LDL cholesterol was similar to the rats fed with
control diet, while HDL cholesterol was higher than in the group of  control rats. Nevertheless, the HDL/LDL
cholesterol was statistically similar  in both the control and microalga-fed groups of rats, whereas this ratio is
greater in the rats fed with fish oil. 
According to the use of microalga as an alternate to fish oil, differences in the enrichment of tissue in ω3 fatty
acids and specifically in EPA were mentioned. Indeed, results reported in Fig. 2 show that the levels of EPA,
obtained for each organ are significantly different from ones obtained in the two other groups (for all studied
organs). In fact, whatever the organ considered (liver, heart or kidney), EPA levels were significantly higher in
rats fed with the freeze-dried microalga diet than in those fed with fish oil or control diets. Moreover, significant
higher amount of DPA was found in the liver and kidney total lipid of the rats fed with the diatom diet than in
those  from rats  fed with  fish  oil  or  with  the  control  diet.  The  n-6/n-3 ratio  in  liver,  heart  or  kidney,  were
significantly different in the three experimental groups, the rats fed the control diet being systematically higher
than in the two other groups. In addition, this ratio tends to be lower in the rats fed the freeze-dried microalga
diet by comparison with those fed the fish oil one. These results showed that a freeze-dried O. aurita diet could
be considered as an alternate source to fish oil in regulation of blood parameters involved in lipid metabolism
and in the enrichment of tissue in  ω3 fatty acids and specifically in EPA. This enrichment into EPA at the
expense of Ara incorporation into total  lipids of liver,  heart and kidney could have beneficial effects  in the
cardiovascular disease prevention as described with fish oil. Moreover, when intact microalgae are used in diet,
the effect of the ω3 fatty acid role could be potentiated with pigment content such as Fuco or other Cars. These
results are in line with those published by Rao & Rao [81] and Micallef & Garg [82], who found a synergistic
action between pigments, fatty acids and phytosterols on plasma lipid concentration decrease, on inflammatory
response and thus on cardiovascular disease risk prevention. These molecules that are naturally contained in O.
aurita make this organism a major actor in human nutrition as an alternate to fish oil.
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Pigments
Three major classes of photosynthetic pigments occur among microalgae: Chls and derivatives, Cars (carotenes
and xanthophylls) and phycobilins, which together represent hundreds of molecule purification [83]. Considering
their  high  structural  diversity  and  the  possibility  to  pharmacomodulate  these  molecules,  the  potential  of
microalga pigments to  obtain  molecules of therapeutical  interest  is  very high.  Because of their  lability and
difficult purification, the biological activity of most molecules  remains unstudied [27,59]. A large number of
studies  designed  to  purify  and  identify  bioactive  molecules  from microalgae  have  lead  to  the  isolation  of
pigments. These purified pigments usually have a high activity on pharmacological and cellular effectors, at very
low concentrations.
Antioxidant, anti-inflammatory and antimutagenic activities
Oxidative stress is a major cause of inflammatory events implicated in a large number  of diseases,  such as
cancer,  neurodegenerative  and  cardio-vascular  diseases,  or  diabetes.  The  antioxidant  and  anti-inflammatory
activities  of  microalga  pigments  is  widely  demonstrated  and  evidenced  in  numerous  in  vitro  free  radical
scavenging assays and  in vivo  assays. The antiradical capacity of metal-free Chl-derivatives such as chlorins,
pheophytins, and pyropheophytins is much weaker that the corresponding metallo-derivatives. Protoporphyrin
methyl ester and its magnesium chelated derivative, as well as  pheophorbide  b and pheophytin  b,  were also
identified as strong antioxidant molecules [84]. The ability of the porphyrin ring to transfer electrons explains the
antioxidant  activity  of  Chls and  derivatives.  The  high  antioxidant  activity  of  pheophorbide  b,  compared  to
pheophorbide a, suggests that the presence of the aldehyde function may also be critical to this activity [85]. The
antioxidant  properties  of  Chls  and  Chl-derivatives  disappear  in  the  presence  of  light  [86].  Metal-free  and
metallo-Chl derivatives have also antimutagenic activities, as demonstrated using a bacterial mutagenesis assay
[87-88].  Microalgal  carotenoids  (e.g., zeaxanthin  (Zea),  astaxanthin  (Asta)  (9))  and  epoxycarotenoids  (e.g.,
neoxanthin) have strong antioxidant activities in vitro and in vivo in animal models. Particularly, Asta has a great
potential to prevent cancer, diabetes and cardiovascular diseases [89-90]. The presence of the hydroxyl and keto
endings on each ionone ring explains Asta unique features, such as the ability to be esterified [91], a higher
antioxidant activity and a more polar configuration than other Cars [92]. Epidemiologic studies demonstrate an
inverse relationship between cancer incidence and dietary Car intake or blood carotenoid levels, but intervention
trials using a high dose of carotene supplements did not show protective effects against cancer or cardiovascular
disease. Rather, the high risk population (smokers and asbestos workers) showed an increase in cancer cases in
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these trials [93]. Phycocyanin c and phycoerythrin also exhibit antioxidant and anti-inflammatory activities [94-
96].  As  a  conclusion,  most  microalga pigments  exerts strong  in  vitro  antioxidant  activity,  but  additional
intervention trials are required to precise their absorption, metabolism and potential as natural antioxidant, anti-
inflammatory and antimutagenic compounds in vivo.
Cytotoxicity
A large number of studies performed in cancer cells grown  in vitro clearly demonstrate the antiproliferative,
cytotoxic and pro-apoptotic activities of Chl derivatives, Cars, and phycobilins [27]. Moreover, several studies
designed to purify antiproliferative molecules from marine microalgae have led to the isolation of carotene (Zea)
[83,91] and epoxyCars (e.g.,  Fuco, violaxanthin (Viola) (10)) [78,92]. Fuco is the prototypical example of a
microalgal cytotoxic pigment with an important therapeutic potential. Its strong antiproliferative, cytotoxic and
pro-apoptotic  activities , at concentrations inferior to 1 µM, have been widely studied and demonstrated on a
large number of human cancer cell lines from various tissular origin (lung, breast, prostate, lymphoma, gastric,
uterine, neuroblastoma,etc) [98-102]. The molecular mechanisms involved in the cytotoxic activity of Fuco are
not  completely  understood,  but  various  cellular  targets  of  Fuco  have  been  identified.  Because  of  its
hydrophobicity, Fuco easily crosses and integrates cell membranes. It inhibits mammalian DNA-dependent DNA
polymerases [103], protects against ROS and UV-induced DNA injury [99,104-107], down regulates cyclins and
CDK expression, disturbs major transduction pathways controlling cell survival and transcriptional activation of
genes  involved  in  resistance  to  apoptosis  and  anticancer  drugs  in  cancer  cells.  (MAPK,  NF-κB  [99,101],
p21WAF/Cip1  CDK  inhibitor  [108],  Bcl-xL  [109-110]).  Fuco  also  enhances  Gap  junction  intracellular
communication,  an important  process in  the  control  of cell  growth,  differentiation,  apoptosis  induction and
diffusion  of  anticancer  drugs  [111].  Intestinal  absorption  and  metabolism  of  dietary  Fuco  into  its  major
metabolite fucoxanthinol was demonstrated in mices, but not in humans. Absorption studies in humans indicated
that less than 1 nmol.L-1 is found in plasma after a 1 week diet containing Fuco- rich diet [112]. In the same way
as Fuco, a large number of microalga pigments were identified as cytotoxic at very low concentrations in cancer
cells.  They belong to the epoxyCars class (e.g.,  Viola [96],  halocynthiaxanthin [100,103,113-114],  peridinin
[114-117]), to Chl derivatives (e.g., Chl a, pheophytin a, pheophytin b, pheophorbide a) or to phycobilins (e.g.,
phycocyanin) [92]. Moreover, for some of them, their anticancer activity was confirmed after per os absorption.
As  an  example,  in  the  pathogen-free  ddY strain  mice,  the  development  of  skin  tumors  induced  by  12-O-
tetradecanoylphorbol-13-acetateis suppressed when 1 µmol peridinin is added in dietary water [118]. For most
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molecules, intestinal resorption, bioavailability and metabolism are unknown. Besides, their effect in noncancer
cells and immune cells is mostly unexplored. Understanding their pharmacological activity in human cells may
allow to obtain potent selective anticancer pharmaceutics.
Ref 95
Multi-drug resistance reversion in cancer cells
Microalgae pigments may have interest to restore drug sensitivity or reverse multi-drug resistance in cancer
cells,  as  some  of  them  inhibit  or  down-regulate  drug  efflux  pumps.  As  examples,  neoxanthin  increases
rhodamine  123  accumulation  in  multi-drug  resistance  (MDR)  colon  cancer  cells  [113],  inhibits  the  P-
glycoprotein (P-gp) efflux pump and reverses MDR in doxorubicin-resistant MCF-7 cells and hmdr1- transfected
L1210, at 4 and 40 µg.mL-1, respectively [119]. Viola and violeoxanthin are effective MDR modulators in Colo
320, at  4 and 40  µg.mL-1,  respectively [120].  Mod erate P-gp inhibition by Viola was observed in hMDR1-
transfected L1210 and MDA-MB-231 expressing the MRP1 pump (HTB26) at 20 µg.mL-1 [121-122].  In the
same  way,  a  significant  reduction  of  P-glycoprotein  expression  R-HepG2  cells,  at  both  transcriptional  and
translational levels, was observed when cells were treated with pheophorbide a [123]. 
Antiangiogenic activity
Fuco and its physiological metabolite fucoxanthinol have antiangiogenic effects, as demonstrated in the blood
vessels  and HUVEC tube formation assays. In SCID mice injected subcutaneously with 107 HUT-102 cells,
fucoxanthinol  did  not  affect  tumor  incidence,  but  significantly  slowed  tumor  growth.  It  also  significantly
decreased microvessels outgrowth, in a dose-dependent manner, in an ex vivo angiogenesis assay. 
Use as fluorescent probes
The physicochemical  characteristics  of  phycobilins,  Chl  and  Chl  catabolites  make  them suitable  for  use as
fluorescent  probes  for  cellular  and  tissular  analysis  (e.g.,  cell  sorting,  cytofluorescence,  flow  cytometry,
histofluorescence, binding assays, ROS detection, labeling of pathological or apoptotic cells, etc). Phycocyanin
or  phycoerythrin-coupled antibodies are  common reagents available  for  research and medical  use,  in which
phycobilins act as powerful and highly sensitive fluorescent probes (for reviews, see [96]).
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Other preventive or therapeutical use
Microalgal  pigments  have  demonstrated  their  lack  of  toxicity  and  biological  activity  in  a  wide  range  of
biological  applications,  including  prevention  of  acute  and  chronic  coronary  syndromes,  atherosclerosis,
rheumatoid arthritis,  muscular dystrophy, cataract and neurological disorders.  They are also recommended to
protect the skin and eyes against UV radiation [124-125]. Lutein is one of the major xanthophylls found in green
microalgae. It selectively accumulates in the macula of the human retina, protects the eyes from oxidative stress,
and acts as a filter of the blue light involved in macular degeneration and age-related cataract [112,126-127].
Fuco anti-allergic activity was recently evidenced using a rodent mast cells model [127].  It  could also have
interest to limit the risk of obesity [127,129]). Because of their antioxidant and anti-inflammatory activity, most
microalga pigments have neuroprotective effects in cultured rat cerebellar neurons, and hepatoprotective effects
in hepatocytes grown in vitro (e.g., phycocyanin, phycoerythrin) [96]. Besides, some studies have demonstrated
antiviral and antifungal activities for some pigments (e.g., allophycocyanin, phycocyanin) [96, 130].
Potential and obstacles to a possible pharmaceutical development of microalgae pigments and derivatives
The lack of oral toxicity of microalgae pigments may be due to a weak intestinal resorption but also suggests a
possible  pharmaceutical  development  for  these  molecules  (e.g,  [24]).  Most  microalga  pigments  are  labile
molecules, sensitive to light and oxygen, and it is highly probable that their half-life in a physiological context is
short  [131].  This  lability  has  interest  when considering new  applications,  but  is  also  a  limit  to  their
pharmaceutical  development.  It  also  explains  the  high  price  and  low  availability  of  pigments  standards,
necessary to set up intervention trials and clinical assays. Consequently, there  is a lack of  in vivo studies on
absorption, metabolism and pharmacokinetics of microalga pigments [27]. Moreover, dozens of pigments and
derivatives  are  unstudied  because  no  standard  is available.  It  is  essential  to  carry  on  the  development  of
economically viable industrial processes to obtain high amounts of pigments and derivatives (selection of over-
producing  species  and  strains,  definition  of  physiological  conditions  giving  the  best  production  yields,
optimization  of  eco-extraction  and  purification  processes,  development  of  chemical  and  chimioenzymatic
synthesis). As an example, the average carotenoid concentration in dry microalgae is 0.1-2% (w:w). When grown
under optimized conditions of salinity and light intensity,  Dunaliella produces up to 14% β-carotene [72,130-
132]. Purification from natural sources is much more expensive than chemical synthesis, but has the advantage
of providing pigments in their natural isomer proportions (e.g., carotene) [72,130-132]
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ABIOTIC STRESSES: A CONVENIENT WAY TO INDUCE THE METABOLIC REORIENTATION 
AND INCREASE THE PRODUCTION OF SELECTED BIOACTIVE COMPOUNDS.
As microalgae play a major role in CO2 uptake [2,22], numerous studies deal with effects of abiotic stresses on 
algal biology and metabolism. The main objectives of some of those studies were to predict how and what algae 
will cope with climatic change and increasing pollution. The commercial exploitation of the natural microalgal 
diversity for the production of carotenoids and PUFAs has already started up with few strains such as Chlorella 
vulgaris (Trebouxiophyceae), Dunaliella salina (Chlorophyceae), Haematococcus. pluvialis (Chlorophyceae) 
[133-134] and O. aurita (Bacillariophyceae). In this section, the impacts of abiotic stresses such as light, UV-ra-
diation, nutrient starvation, temperature and metals on microalgal metabolism and on the production of biologi-
cal active compounds is reviewed. 
Light
More than terrestrial plants, microalgae display a diversity of light harvesting pigments (Table 1) allowing 
photosynthesis at different depths according to pigment content. Photosynthetic apparatus of most microalgae 
acclimates to light level and light quality by optimizing pigment content and composition [135-141]. Microalgae 
are confronted with variations of light by movements in the water column and emersion for coastal benthic 
species. To cope with high sunlight intensities, microalgae have developed different photoprotective 
mechanisms. One of these, the xanthophyll cycle, consists in the reversible conversion of Viola, antheraxanthin 
and Zea in green algae and in the reversible conversion diadinoxanthin and diatoxanthin in brown algae [91,141-
142]. Acclimation to low irradiance intensity or blue enriched light increases Car synthesis such as Fuco [140]. 
The photoprotection or the low photoacclimation leads carbon to Cars whereas in nonstressfull conditions, C 
serves mainly to growth (cell wall edification). In the marine diatom Haslea ostrearia, C fixation by β-
carboxylation is almost equal to that in the C3 pathway whereas under low irradiation C3 fixation dominates 
[144]. Light intensity has also an impact on lipid synthesis, PUFAs: EPA, was significantly higher under low 
light, and saturating fatty acids and DHA levels were higher under high light in Pavlova lutheri [140]. EPA and 
DHA are now recognized as having a number of important neutraceutical and pharmaceutical applications. 
UV-radiation
Microalgae experience high levels of UV-radiation in shallow areas, low turbide habitats or during low tides 
when they are deposited on intertidal flats. Several authors have shown that UV exposure increases carotenoid 
17
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
Current Pharmaceutical Biotechnology                                                                                   Mimouni et al.
content [145-146] and, in some Bacillariophyceae, MMAs synthesis [147-148]. Guihéneuf et al. [149] have 
shown that a 8-day exposure to UV decreases the PUFA content, EPA by 20% and DHA by 16% in Pavlova 
lutheri but not in Odontella aurita in which the PUFA content remains unchanged. As other environmental 
stresses, UV radiation stimulates the intracellular ROS production [150-151] triggering antioxidative defence 
such as antioxidative enzyme activities and antioxidant compounds (glutathione, α-tocopherol, ascorbate, etc). 
Nutrient starvation
The reorientation of the metabolism induced by nutrient starvation is illustrated by the accumulation of Asta in 
H. pluvialis under N-limitation and P- or S-starvation [133,152-153]. Asta accumulation is related to a massive 
increase in carbohydrate content up to 63% of the cell dry weight [154] and an increase of lipid content in the 
cytoplasm. In the Crytophyceae Rhodomonas sp., N-starvation triggers a rapid decline in N-containing 
compounds causing an almost complete loss of phycoerythrin [155]. Riyahi et al. [156] have shown that the 
production of β-carotene in Dunaliella salina was increased with nitrate 1 mM and salinity 30%, On the other 
hand, in the microalga Tradydiscus minutus (Eustigmatophyceae), N-starvation brings about a nearly 50% drop 
in triacylglycerols (TAGs) containing EPA, and also a decrease of TAGs containing Ara, while P-starvation has a
sizable effect on those TAGs that contain two or three Ara [157]. Many microalgae promote a shift in lipid 
metabolism by producing substantial amount (20-50% of dry weight) of TAGs as lipid storage during the 
stationary phase when nitrate becomes depleted [158]. The amount of EPA partitioning into TAGs varies 
according to strains and also during the different phases of growth within a species.
Metals
Some metals such as Cu, Fe, Zn are essentials for cell metabolism since they are components of electron 
transporters involved in photosynthesis and respiration, some enzymes, etc. When metals are present in excess, 
they induce an oxidative stress [159-160] and antioxidant defense mechanisms already cited above. To cope with
metals in excess, many microalgae excrete exopolysaccharides that adsorb metals in the medium and prevent 
them to enter inside the cells [161-162]. Polysaccharide depolymerization by different procedures allows the 
obtention a variety of oligomers with potential applications in therapeutics and in biotechnology [10]. However, 
in the presence of Cd, the xanthophyll cycle in Phaeodactylum tricornutum is inhibited [163]. The impact of 
metals depends on their speciation and the growth medium pH [164].
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Temperature
Microalgae can synthetize VLCPUFA as major fatty acid components [165]. Experiments in controlled 
conditions are necessary in order to select species producing those PUFAs, in what conditions, at what stage of 
their growth, and in what lipid class. Tonon et al. [158] have shown than fatty acids accumulate during the 
stationary phase of growth when nitrate concentration in the growth medium was low. EPA production is higher 
at 8°C than at 25°C in the red microalga P. purpureum [166]. In the marine diatom Nitzschia leavis cultivated at 
15, 19 and 23°C, growth is enhanced at the highest temperature but the lowest temperature favours the 
distribution of PUFAs in phospholipids and increases EPA content in TAGs [167]. As in terrestrial plants, the 
increase of PUFAs in membrane was suggested to be a strategy to maintain membrane fluidity under low 
temperature. 
LARGE-SCALE CULTURE AND BIOMOLECULE PRODUCTION
Microalgae are a source for a variety of bioactive compounds. However, they remain largely unexplored and,
until now, very few commercial achievements of microalgal biotechnology have emerged [168]. During the last
decades, researchers and engineers have developed several cultivation technologies that are still in use today.
Seen very often as obvious, the subsequent culture of a given microalgae can be more difficult than expected in
the  attempt  to  up-scaling.  Numerous  drawbacks  and difficulties await  the  entrepreneur  wishing to  set  up  a
commercial  production.  The  choice  of  photobioreactors,  light  systems,  control  for  pH,  CO2 etc..  batch  or
continuous cultures, management of nutrients, water supply, water treatment onward and outward as well as the
energy needed will constitute a strategic debate. Concerning the biological aspects, once the proper selected
strain is chosen, the type of culture system, the feeding strategies (photoautotrophy, heterotrophy, mixotrophy
reviewed hereafter), the confrontation with pathogens, contaminants and predators will enter in the game.
Photoautotrophic production
Photoautotrophic productions use light as the source of energy thank to photosynthesis and CO2 as the source of
carbon.  They are  currently  processed with  either  open ponds or  closed systems,  that  can use  sun light  and
artificial light. However, the major constraint that phototrophic production must address is how efficiently light
is used. Indeed, productivity is tightly related to the surface to volume ratio of the cultivation system and many
recent technological developments tended to improve this ratio.
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Originally,  open-ponds  and  raceways  were  used  for  microalgae  production,  but  the  quest  for  increased
productivity  and  better  control  led  to  the  development  of  closed  photobioreactors.  The  latter  are  usually
recognized  as  achieving  higher  biomass  productivity  than  open  systems  [60,169-170].  Nevertheless,  the
maximum biomass productivity does not necessarily match the maximum productivity for a particular molecule,
neither  the  maximal  economic  efficiency  [171].  It  is  beyond  the  scope  of  this  article  to  enter  into  the
argumentation of the pro and contra open ponds versus photobioreactors. The solution might lie in between when
the  two  technologies  will  be  integrated  in  the  same  production  line.  Controlled  production  system  like
photobioreactors renders easier  to  explore  the  metabolic  versatility  of  microalgae  with  different  production
strategies.  Despite  their  high initial  investment,  photobioreactors provide a  variety of attractive  benefits  for
bioactive molecule production, when compared to open systems. First,  they make possible monospecific  and
axenic cultures as well. They also are characterized by reproducible cultivation conditions and accurate control
for abiotic factors such as temperature, pH, irradiance, evaporation and hydrodynamics. The production of a
particular  molecule  can  take  advantage  of  these  controls  since  abiotic  factors  can  substantially  impact  the
biochemical composition of microalgae, as discussed above.
Most of the commercial productions use photoautotrophic cultivation processes, with pigments, health food and
aquaculture being the main markets. Several commercial companies produce Asta with Haematoccoccus : Mera
Pharmaceuticals  (Hawaii)  reports  a  biomass  production  of  about  6.6  T/year  using  closed  tubular
photobioreactors. Similar culture systems have been used by Algatechnologies (Israel) and Fuji Health Science
(Hawaii). However, the production cost of Asta with Haematoccocus is still high because of physiological (slow
growth rate) and technical (two-stage production process) constraints. Thus  from the economic point of view,
Asta produced with Haematoccocus can hardly compete with the synthetic pigment [92]. 
Dunaliella natural  β-carotene  is  another  widely  distributed pigment  from microalgae.  Its  global  production
through   autotrophic cultivation is estimated at about 1.2 T/year [12]. Two cultivation processes are currently
used  for  β-carotene  production.  Betaten (Adelaide Australia)  or  Aquacaroten (Subiaco,  Australia)  grow this
microalgae in unmixed open ponds and Betaten reported a β-carotene production of about 13 T/year (about 400
ha of culture area). The associated production costs appear relatively low considering the optimal climate and,
unlike other systems, no pumping is required [172]. Raceway ponds (intensive mode) are operated by the Nature
Beta  Technologies  company (Eilat,  Israel),  reporting a  β-carotene  production of  3  tonnes  per  year.  Several
studies have been attempted to grow Dunaliella in closed photobioreactors, although up to date, none of these
trials led to any significant production even at the pilot scale [173]. Several other little companies commercialize
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a variety  of  microalgae grown photoautotrophically for  their  high amount  in EPA and DHA.  For  example,
Isochrysis sp. is produced by Innovative Aquaculture Products Ltd (Lasqueti Island, Canada) and the diatom O.
aurita is produced by BlueBiotech InT (Kollmar   Germany) and Innovalg   (Bouin, France).   In the latter,  O.
aurita is  grown  photoautotrophically  in  open  air  1,000  m2 raceways  and  co-cultured  with  the  macroalgae
Chondrus cripus, for increased productivity [65].
Heterotrophic production
Studies on microalgae heterotrophy were initiated in the 60s and demonstrated that some species could grow on
organic carbon sources, such as sugars or organic acids, replacing the traditional support of light energy. The
number of studies further increased in the 2000s with the growing interest for biofuel from microalgae. Among
the microalgae species currently cultivated, only a few (e.g., Chlorella protothecoides, Crypthecodinium cohnii,
Schizochytrium limacinum, Haematococcus  pluvialis)  have  been successfully  grown heterotrophically  [174].
Conversely to photoautotrophy where productivity is related to the illuminated area of the culture, productivity
for  heterotrophic  cultures  relies  on  organic  carbon  concentration  in  the  bulk  volume  of  the  culture.  This
facilitates the up-scaling for commercial production and usually results  in higher  productivity,  with biomass
production being one  order  of  magnitude  higher  than for  photoautotrophically grown cultures  [175]  and  in
reduced production, harvest and maintenance costs. For instance, high biomass concentration (45 g L−1) and
volumetric productivity (20 g L−1 d−1) were achieved in heterotrophic cultures of Nitzschia alba [176].
Heterotrophic culture requires  axenic conditions,  a  major  drawback when compared to  photoautotrophy.  As
pointed out by Bumback et al. [177], any, even minor, contamination introduced with the inoculum could easily
outcompete  the  microalgal  species  for  the  organic  carbon  source.  The  prerequisite  for  axenicity  and  the
additional care for its maintenance necessarily impact the production costs. Additionally, heterotrophic culture
might not bring the same diversity and the same biochemical composition as reached with photoautotrophy. Yet,
Perez-Garcia et al. [174] reported the possibility to produce lutein with Dunaliella sp. and Asta with Chlorella
zofingiensis grown heterotrophically.  Wang & Peng  [178] reported the first growth-associated biosynthesis of
Asta  with  Chlorella zofingiensis heterotrophic  cultures  using  glucose  as  organic  carbon source.  This  study
suggested that maximal biomass and Asta production could be obtained simultaneously by a one stage culturing
rather than the two stage process that was proposed for  Haematococcus.  Although commercial production of
Asta with heterotrophic Chlorella zofingiensis culture has not yet been reported, this species may be a promising
alternative  to  Haematococcus for  the  mass  production  of  Asta.  Besides,  commercial  production  of
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heterotrophically grown  Chlorella in fermentor is  common in Japan and Korea,  mainly for  aquaculture and
health food applications [179]. Martek (USA) also successfully produces DHA health food with heterotrophic
Crypthecodinium cohnii cultivation [180].
Mixotrophic production
If mixotrophy is defined so as to include osmotrophy, most of microalgae can be considered as mixotrophic.
Many microalgae can grow on dissolved organic carbon [181] and, under inorganic nitrogen stress, use organic
sources of nitrogen [182]. 
When microalgae are grown with CO2 as the sole carbon source, light provides the energy necessary for biomass
production. However, under photoautotrophic conditions, growth is often limited by light availability and, during
the night,  the productivity is  further  reduced by respiration.  Mixotrophic microalgae can concurrently drive
phototrophy and heterotrophy to utilize organic energy and both inorganic and organic carbon substrates, thus
leading to a  synergetic effect  of the two processes that  enhances the  culture  productivity.  Yang  et al.  [183]
demonstrated that biomass yield on the supplied energy was four folds higher for true mixotrophically grown
Chlorella  pyrenoidosa than  for  the  photoautotrophic  culture.  They  also  highlighted  that  cyclic  autotrophic/
heterotrophic cultivations, could lead to even more efficient utilization of energy for biomass production than the
true  mixotrophy.  Moreover,  mixotrophy  can  overcome  light  limitation  occurring  at  high  densities.  This
mechanism has been demonstrated to be important for Scenedesmus obliquus [184] and is suggested to be widely
spread among mixotrophic microalgae in general.
Hence, high productivity is one of the major benefits associated with mixotrophy. For some microalgae, the
growth performance under mixotrophic conditions can even exceed that achieved with heterotrophic cultures.
Indeed,  Pulz  &  Gross  [12]  pointed  out  that  the  maximum  specific  growth  rate  of  Chlorella vulgaris and
Haematococcus pluvialis growing mixotrophically was the sum of the photosynthetic and heterotrophic specific
growth  rates.  Besides,  Stadnichuck  et  al.  [185]  reported  higher  Chl  a,  carotenoids,  phycocyanin  and
allophycocyanin  content  in  Galdieria  partita grown  mixotrophically  than  in  heterotrophically  cultures.
Mixotrophy can therefore overcome some of the drawbacks experienced with heterotrophic cultures [186] and
might be an efficient means for enhanced production of light-induced pigments in microalgae. However, as for
heterotrophic cultures,  mixotrophic cultures require axenic conditions to prevent bacteria from outcompeting
microalgae for organic substrates. Research will be needed to cope with the risk of favouring the prokaryotic part
in the culture. To date, the processing of mixotrophic cultivation implies the availability and maintenance of
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axenic strains, the investment for sterilizable photobioreactors and higher operation costs. However, the higher
productivity achieved with mixotrophy cultures could balance these drawbacks.
It  is  well  documented  that  some  economically  important  microalgae  can  be  grown  mixotrophically
(Haematococcus pluvialis, Scenedesmus acutus, Chlorella vulgaris, Nannochloropsis sp.). However, despite the
indisputable assets of mixotrophy, only one company reported the use of mixotrophic processes for industrial
Asta production. Indeed, BioReal (Sweden) was the first company in the world to produce and commercialize
from 15 to 30 T/year of Asta-rich biomass using mixotrophy culture in indoor closed photobioreactors [172].
CONCLUSIONS AND FUTURE DIRECTIONS
Microalgae represent a subset of single cell microorganisms that generally grow autotrophically using carbon
dioxide as the sole carbon source and light as energy. They are ubiquitous in nature, occupying every type of
ecological niche. Microalgae represent  a major untapped resource of genetic potential for valuable bioactive
agents  and  fine  biochemicals.  Screening  studies  should  reveal  the  existence  of  new molecules  potentially
interesting for their biological activities. From the basic point of view, the mechanisms of action of the already
marketed  products  should  be  better  established.  For  instance,  it  has  been  reported  that,  beyond  ω-3  and
antioxidants, fish oil also contain peptides having bioactive activity. Many of them have an interest for health
and  pharmaceutical  industries.  In  their  natural  environment,  algae  are  subjected simultaneously  to  different
abiotic factors with daily and seasonal variations that may be stressful, such as tidal movements, temperature,
light levels or UV radiations. To cope with stress, the synthesis of molecules of interest such as antioxidants,
PUFAs and glycerol is increased in tolerant microalgae. More basic research on this point should be performed
to elucidate the metabolic and regulation circuits involved in these productions. This will help to discover what
are the interactions between several abiotic factors and mechanisms involved in the biochemical responses.  In
silico research,  biochemical  characterization  of  microalgal  products  and  in  the  same  way  the  research  of
biological activities of algal extracts seem promising for biotechnology applications. Many molecules produced
by microalgae show a high structural diversity and should be considered as potent bioactive molecules able to
significantly  modulate  human  cell  functions,  in  a  physiological  or  pathological  context,  at  very  low
concentrations. Additional studies of their biological activity  in vivo are required to precise their absorption,
metabolism and interest as potential natural anticancer or cardioprotective agents. The development of efficient
purification processes will stimulate their study and pharmaceutical development.
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The cultivation means to produce bioactive compounds are various. Important are the source of energy and the
biomass yield. The selection for high producing strains, the optimization of culture modes and harvesting and the
management  of  molecule  expression  in  cultures  are  crucial  steps  for  the  future.  Whatever  the  species  and
molecules produced, the harvesting system is an expensive and limiting step that has to be adapted to preserve
together the algae integrity but also the one of the molecule. Ideally, microalgae producers look for strains with a
high valuable-product productivity. However, until now, the main commercial productions rely on a few wild-
type strains and the selection for original strains with a high potential for biotechnology remains a challenge for
the industry. Pioneer studies for strain selection were initiated in the 90s. The combination of mutagenesis to a
selection  procedure  resulted  in  substantially  increased  production  for  pigments  [187],  PUFAs  [188]  or
triacylglycerides [189]. These techniques offer an appealing alternative to GMOs.
Transgenic microalgae can be also used as bioreactor for production of therapeutic and industrial recombinant
proteins [190-191]. To date, a variety of recombinant proteins have been expressed from nucleus and chloroplast
of  Chlamydomonas reinhardtii.  These include  pharmaceutical  proteins,  antibodies,  vaccines,  and others  that
showed a biological activity comparable to the same proteins produced by traditional commercial techniques
[192].  Our groups were quickly intrigued by the potential  of microalgae as a means to produce therapeutic
proteins [193]. A private company was born from this research: Algenics, which is, to date, the first European
privately-held  biotechnology  company  focusing  on  innovative  uses  of  microalgae  to  produce  recombinant
biotherapeutics (http://www.algenics.com). Concerning the use of microalgae as a platform of recombinant
proteins, the recent success led to several patents [194-197] with the successful production of erythropoietin in
Phaeodactylum tricornutum (unpublished work). The production costs for microalgal therapeutic proteins are
very attractive (i.e., the cost for recombinant antibody is estimated to 0.002 US$ and 150 US$ per gram from
microalgae  and  mammalian  cell  culture  respectively  [198]).  Moreover,  this  cost  could  fall  provided  that
recombinant protein production is coupled with recovery of valuable natural product. However, to the best of our
knowledge, no microalgal therapeutic proteins have been yet commercially used.
Microalgae can also be used in biotransformation experiments. In such experiments, immobilized microalgae are
incubated with particular substrates to use the in situ enzymes to produce products. Such a method has been used
to  study  the  potential  of  green  microalgae  such  as  Chlamydomonas  sp. and  Oocystis  sp. to  produce  new
monoterpenes. The molecular engineering described above combined with biotransformation principle opens
many new avenues for algal biotechnology.
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ABBREVIATIONS: Asta: astaxanthin, Car: carotenoids, Chl: chlorophyll, DHA: docosahexaenoic acid, EPA: 
all-Z-eicosa-5,8,11,14,17-pentaenoic acid, Fuco: fucoxanthin, MAAs: mycosporine-lide amino acids, P-gp: P-
glycoprotein, PUFA: polyunsaturated fatty acids, MDR : multi-drug resistance, TAGS: triacylglycerols, Viola: 
violaxanthin, VLC: very long chain, Zea: zeaxanthin
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SUPPLEMENTARY MATERIAL
Fig. S1. Algae represent less than 10% of the total number of identified species. 
The original data [S1] were not including the unicellular species. In order to take into account these organisms, 
we have substituted the number of original species by the number of species found in the AlgaeBase database 
(http://www.algaebase.org/) although this number is probably largely underestimated.
[S1] The World Conservation Union. IUCN Red List of Threatened Species. Summary Statistics for Globally 
Threatened Species (1996–2010). 
http://www.iucnreditlist.org/documents/summarystatistics/2010_1RL_Strats_Table_1.pdf. Accessed 31/01/2012.
Fig S2. Number of publications describing a compound from algae having a biological actvity.
The numbers of publications were taken from the Web of knowledge database 
(http://www.webofknowledge.com/). Search performed in December 2011.
Fig. S3. Exemple of mycosporine-like amino acids.
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Fig. 1.  Main plasma biochemical parameters in rats fed with different diets  .
Glucose,  triacylglycerol  and  cholesterol  levels  were  determined  using  colorimetric  kits  (glucose  RTU,
cholesterol RTU, triglycerides enzymatique PAP 150, respectively, from bioMerieux, Marcy-l’Etoile, France).
Results are expressed (mmol L-1) as mean ± SEM for n = 4 animals. After analysis of variance, the means were
compared  by  Fisher's  least  significant  difference  test.  Means  assigned  different  superscript  letters  were
significantly different (p < 0.05).
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Fig. 2.   Effects of     3 fatty acid marine sources on total lipid     3 fatty acid composition in plasma, liver,  
heart and kidneys in rats fed with different diets.
After extraction of lipids, fatty acid methyl esters were obtained according to the method of Slover and Lanza
[81]. Fatty acid composition was performed on a GC-Focus apparatus as previously described [82]. Results are
expressed (% molar) as mean ± SEM for n = 4 animals. After analysis of variance, the means were compared by
Fisher's least significant difference test. Means assigned different superscript letters were significantly different
(p< 0.05). 
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Table 1. Main chlorophyll and carotenoid types in the various taxons of photosynthetic organisms.
Pigment type Red algae Brown algae Green algae
Phycoeryhthrin, phycocyanin, allophycocyanin + - -
Chl a + + +
Chl b - - +
Chl c - + -
β-carotene Unicellular + +
Fucoxanthin - + -
Violaxanthin + + +
Lutein Pluricellular - +
Zeaxanthin + + +
Canthaxanthin - - -
Xanthophyll cycle - + +
Table   2  .   Total  lipid content (% of  dry weight)  and EPA and DHA content (molar percentage)  of  some
species of microalgae [59-69].
Classes Species Lipid content EPA DHA
Chlorophyceae
Tetraselmis suecica 15-23 1-5 <1
Chlorella sp. 28-32 1-5 <1
Dunaliella primolecta 23 <1 <1
Prymnesiophyceae
Isochrysis sp. 25-33 <1 10-20
Pavlova lutheri 20-25 >20 10-20
Bacillariophyceae
Skeletonema costatum 13 10-20 1-5
Thalassiosira pseudonana 24 15 1
Odontella aurita 7-13 >25 1-2
Phaeodactylum tricornutum 20-30 26 2
Nitzschia sp. 45-47 25-30 <1
Dinophyceae Crypthecodinium cohnii 20 45 <1
Rhodophyceae Porphyridium cruentum 10-15 21 <1
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